### Number of HSCT for autoimmune diseases: 2609

**EBMT Registry - February 2018**

<table>
<thead>
<tr>
<th>Autoimmune disease</th>
<th>Number of HSCTs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multiple Sclerosis</td>
<td>1187</td>
</tr>
<tr>
<td>Haematological</td>
<td>104</td>
</tr>
<tr>
<td>Connective Tissue</td>
<td>666</td>
</tr>
<tr>
<td>Other</td>
<td>608</td>
</tr>
</tbody>
</table>

**Key scientific advances**

- Over 2500 HSCT for autoimmune diseases in the largest database worldwide
- In association, the ADWP continues to add to the evidence-base with prospective studies, registry-based studies and guidelines written with other professional groups outside of Haematology. Our collaborations also now robustly extend outside of Europe, including North and South America and Australia.
- The clinical efficacy of autologous HSCT for some indications AD is now becoming well established. The future challenge is to further optimize transplant protocols to maximize safety and efficacy of this procedure. Health economic considerations and implementation science will also be essential to define how to deliver HSCT best in the context of biological and other modern therapies. Immuneologic studies in the field are ongoing and provide novel aspects in the understanding of the underlying mechanisms that promote long-term drug-free remissions by HSCT in ADs.
- Sustained positive clinical results and enhanced ADWP activity in otherwise refractory AD patients continues to attract patients, clinicians, and healthcare providers in the field. However, the future of this treatment will depend on quality care. We continue to update guidelines for HSCT in specific autoimmune disease groups and delivery of HSCT in AD by JACIE accredited centres.
- AUTOIMMUNE DISEASES ARE THE FASTEST GROWING INDICATION FOR HSCT IN THE EBMT ACTIVITY SURVEY (Passweg et al, Bone Marrow Transplantation, 2018).

### Education

1. Updated recommendations for cardiopulmonary evaluation, screening, patient selection for stem cell therapy in poor prognosis systemic scleroderma.
2. Autologous haematopoietic stem cell transplantation (AH SCT) in severe Crohn’s Disease: a review on behalf of ECCO and EBMT.
3. ADWP / IEWP joint Educational Meeting, Newcastle, UK, 3-5 November 2017; where we explored the interface between autoimmunity, autoinflammatory disease, immunodeficiency and other inherited disorders.
4. ADWP / SAWP joint Educational Meeting, Florence, Italy, 15-17 November 2018 – SAVE THE DATE!

### ADWP – Recent publications